Concepedia

Berris van Kessel

BV

18

Publications

2.1K

Citations

17

H-Index

2002

Active since

Affiliations

University Medical Center Utrecht(Current)

Genmab (Netherlands)

Amsterdam UMC Location Vrije Universiteit Amsterdam

Meander Medisch Centrum

Erasmus MC

Berris van Kessel is an author at University Medical Center Utrecht specializing in radiation oncology, medicine, and cancer research.

Top concepts

Publications per year

2002–2020

18

Publications

18

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen et al. · Blood · 2016 · 371 citations · Full text

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

Inger S. Nijhof, Richard W.J. Groen, H M Lokhorst et al. · Leukemia · 2015 · 261 citations · Full text

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Michael S. van der Veer, Michel de Weers, Berris van Kessel et al. · Haematologica · 2010 · 216 citations · Full text

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

Jakub Krejcik, Kris A. Frerichs, Inger S. Nijhof et al. · Clinical Cancer Research · 2017 · 166 citations · Full text

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

Inger S. Nijhof, Richard W.J. Groen, Willy A. Noort et al. · Clinical Cancer Research · 2014 · 146 citations

Rows per page

1–5 of 18